APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer

CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for the treatment of neurodegenerative diseases such as Alzheimer's Disease (“AD”), Parkinson’s Disease (“PD”), and certain rare dementia and movement disorders, announced today that its Board of Directors has appointed Mark S. Shearman, Ph.D. as Chief Executive Officer. Ming-Kuei Jang, Ph.D., the Founder and Chairman of the Board of APRINOIA, who had led the company as CEO since its inception, has now also assumed the role of President of APRINOIA’s Asia operations.  

Dr. Shearman, who holds a Ph.D. in neuroscience, has extensive experience in pharmaceutical research, drug development and strategic partnerships. Prior to APRINOIA, he held executive leadership positions at Editas Medicine, Applied Genetic Technologies Corporation, Merck KGaA and Merck & Co., and has served as Chair of APRINOIA’s Scientific Advisory Board since 2015. “It is a great honor to assume the post of CEO of APRINOIA. Having been involved with APRINOIA since its inception and having witnessed the tremendous progress in the development of potentially first-in-class precision diagnostics and therapeutics for neurodegenerative diseases, it is exciting to join such an exceptional team. Being part of a new chapter in the company’s history, to advance its diagnostic and therapeutic products to market and provide hope to patients with serious diseases of the brain, for which today, there exists no effective therapy, is a privilege,” said Dr. Shearman.

“On behalf of the APRINOIA Board of Directors, we are delighted to appoint a leader of Mark’s caliber and experience to lead the Company as CEO, to lead APRINOIA to achieve our mission and guide APRINOIA through the next phase of growth and expansion. APRINOIA’s vision remains the same, to help individuals worldwide who are impacted by neurodegenerative diseases through the development of innovative products that redefine treatment possibilities,” said Dr. Jang. “Mark has domain expertise, experience in drug discovery and development, as well as proven abilities to drive growth, and successful strategic planning and execution,” Dr. Jang added.

In addition to Mark S. Shearman, Ph.D., APRINOIA has assembled a strong leadership team to drive growth of the company, which includes Brad Navia, M.D., Ph.D., as Chief Medical Officer, Brian Achenbach as Chief Financial Officer, Lana Gladstein, J.D., as Group General Counsel and interim Chief Operations Officer, and an extended management team, including Paul Tempest, Ph.D., as Head of Medicinal Chemistry, Lili Zhang, Ph.D., as Head of Preclinical Development, Masaomi Miyamoto, Ph.D., as Japan Site Head, Dorothy Yen, M.D., Ph.D., as China Site Head, and Matthew Chan, as Hong Kong Site Head.

APRINOIA is focusing on tauopathies and synucleinopathies, that affect approximately 50 million and 10 million people worldwide, respectively. Collectively, they account for most cases of dementia and movement disorders, resulting in devastating emotional and socio-economic consequences, including prolonged hospitalizations, nursing home placement and death. APRINOIA received an Orphan Drug Designation from the U.S. Food and Drug Administration (the “FDA”) in 2017 for APN-1607 (INN: florzolotau (18F)) as a diagnostic agent for Progressive Supranuclear Palsy (“PSP”) and plans to file an IND with the FDA in the fourth quarter of 2023 to launch a single Phase 3 global trial for APN-1607 in PSP. APRINOIA also has a Phase 2 program in the United States and, through a collaboration, a Phase 3 program in mainland China for the diagnosis of AD. APRINOIA’s APN-1607 PET tracer has been validated in more than 3,000 patients. On the therapeutics front, APRINOIA is evaluating the safety of APN-mAb005 in healthy volunteers in a Phase 1 clinical trial and is optimizing its protein degrader candidates for tau and a-synuclein toward IND-enabling preclinical studies.

About APRINOIA

APRINOIA Therapeutics Inc., is a global clinical-stage biopharmaceutical company, headquartered in Cambridge, MA, developing novel therapeutics and precision diagnostics for the treatment of neurodegenerative diseases.

APRINOIA Investor Contact

Matt Hughes
mhughes@allelecommunications.com



APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer

TIN LIÊN QUAN

Beam Therapeutics to Participate in the 43rd Annual Cowen

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...

Lyra Therapeutics Announces Appointment of John Bishop,

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company...

Molecular Partners to Present at SVB Leerink Global

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...

Rob Hitchcock Named SelectHealth President and Chief

Salt Lake City, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Rob Hitchcock has been named as president and chief executive officer for SelectHealth and will also...

Aberdeen International Announces Appointment of Martin

TORONTO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Aberdeen International Inc. (“Aberdeen” or the “Company”) (TSX: AAB F:A8H, OTC:AABVF) is pleased to announce...

THỦ THUẬT HAY

Cách nhận biết iPhone đã qua sửa chữa rất đơn giản mà bạn nên biết

Có nhiều lỗi trên iPhone khi sử dụng lâu dài mới phát sinh. Vì thế trong bài viết này mình hướng dẫn các bạn cách nhận biết iPhone đã qua sửa chữa rất đơn giản.

Hướng dẫn sắp xếp biểu tượng trên iPhone theo ý thích cá nhân không cần jailbreak

Với iPhone thì bạn sẽ phải jailbreak thiết bị để có thể sắp xếp vị trí các icon trên màn hình chính theo ý thích. Giờ đây, TECHRUM xin chia sẻ cách thực hiện đơn giản hơn mà không cần phải jailbreak.

Tổng quan về Office Deployment Tool

Office Deployment Tool bao gồm hai file: setup.exe và configuration.xml. Để làm việc với công cụ này, bạn có thể chỉnh sửa file cấu hình để xác định tùy chọn bạn muốn, rồi chạy setup.exe từ dòng lệnh. Ví dụ, bạn có thể

Hướng dẫn cách thiết lập đo tốc độ mạng trên Speedtest

Speedtest là dịch vụ trực tuyến giúp người dùng đo tốc độ mạng internet của nhà mạng mình đang dùng như Viettel, FPT hay VNPT

Đây là 7 cách khắc phục lỗi Instagram không hoạt động

Instagram được biết đến là một nền tảng mạng xã hội phổ biến trên toàn thế giới. Người dùng Instagram có thể chia sẻ những khoảnh khắc đời thường, nhắn tin hay thậm chí kinh doanh trên nền tảng này.

ĐÁNH GIÁ NHANH

Điểm danh các ứng dụng tra cứu điểm thi 2023, phụ huynh & học sinh không được bỏ qua

Còn chưa đầy 2 tháng nữa, các bạn học sinh trên toàn quốc sẽ chính thức bước vào kỳ thi chuyển cấp lên 10 và THPT Quốc gia 2023. Hiểu được điều này, Trangcongnghe.vn đã tổng hợp các ứng dụng tra cứu điểm thi cực hay

Mở hộp và đánh giá nhanh Oppo A39: máy đẹp, gọn nhẹ, độ hoàn thiện cao

Với ngoại hình tương tự như F1s cùng mức giá dễ chịu là 5 triệu đồng, Oppo A39 sớm trở thành sản phẩm được săn đón nhất trong mùa mua sắm cuối năm.